Drug Metabolism Letters

Zhiyang Zhao
Amgen
Cambridge, MA
USA

Back

Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

Author(s): Punam Sandhu, Paul A. Andrews, Maribeth P. Baker, Kenneth A. Koeplinger, Eric D. Soli, Thomas Miller, Thomas A. Baillie.

Abstract:

The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.

Keywords: Vorinostat, histone deacetylases, glucuronidation, β-oxidation, 4-anilino-4-oxobutanoic acid

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 1
ISSUE: 2
Year: 2007
Page: [153 - 161]
Pages: 9
DOI: 10.2174/187231207780363642
Price: $58